A phase I study of a multi-modal schedule with Corynebacterium parvum.

: A Phase I study of an immuno-chemotherapy regime was carried out using C. parvum as an immune-modulator. 14 women were studied. All received doses of C. parvum ranging from 2.5 mg to 21 mg administered in 1 litre of dextrose saline over 4 h. No evidence of tumour enhancement was observed.